WelcomeUser Guide
ToSPrivacyCanary
DonateBugsLicense

©2025 Poal.co

292

Anyone here have the expertise to evaluate the study?

https://www.nejm.org/doi/full/10.1056/NEJMoa2115869

Anyone here have the expertise to evaluate the study? https://www.nejm.org/doi/full/10.1056/NEJMoa2115869

(post is archived)

[–] 1 pt
  • "Adaptive design trial protocol" + "master statistical analysis plan" = statistical magic
  • They say they measured hospitalization, but also counted "proxy hospitalization" in "mobile hospital-like services"
  • They gave ivermectin only for 3 days (way too short)
  • They started with 679 people in the treatment group and in the placebo group. Preconditions and chronic diseases were unevenly distributed between these groups => the trial was too small for useful results
  • 21 vs. 24 deaths - deaths don't count in this study